1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
GSK plc

GSK plc

GSK
GSK plcUS flagNew York Stock Exchange
50.04
USD
-1.72
- -
100.22BMarket Cap
GSK plc
GSK
(New York Stock Exchange)

Recent

price

50.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
13.94
13.62
13.45
13.72
11.96
12.38
14.35
15.45
15.68
17.06
12.24
12.34
14.57
14.97
15.39
16.13
16.25
Revenue per Share
0.8
2.62
2.29
2.81
1.43
4.36
0.47
0.78
1.84
2.35
2.89
2.19
7.43
2.43
1.26
2.82
2.89
Basic EPS, GAAP
2.54
2.45
1.45
2.86
1.78
0.35
2.13
2.41
3.37
2.96
3.26
2.65
2.56
2.18
1.75
2.35
2.36
Free Cash Flow per Basic Share
1.57
1.69
1.94
1.9
2
2
2.49
2
2
2
2
2
1.72
1.11
1.2
1.27
1.29
Dividend per Share
3.04
2.37
1.01
1.16
-0.38
-0.03
-2.08
-2.63
-0.7
2.97
4.07
4.64
2.84
4.24
4.49
5.71
6.41
Book Value per Share
-1.18
-1.36
-3.96
-2.94
-3.7
-6.7
-10.17
-10.13
-9.83
-11.7
-9.85
-9.64
-5.6
-4.34
-4.62
-3.86
-3.97
Tangible Book Value per Share
2,036
2,011
1,965
1,932
1,923
1,932
1,944
1,954
1,966
1,979
1,990
2,001
2,013
2,026
2,038
2,026
2,017
Basic Weighted Avg Shares
28,392
27,387
26,431
26,505
23,006
23,923
27,889
30,186
30,821
33,754
24,354
24,696
29,324
30,328
31,376
32,667
32,780
Sales/Revenue/Turnover
12.71
27.54
22.98
22.21
18.72
10.99
21.61
20.08
22.91
18.64
18.8
19.75
22.95
24.22
17.66
25.52
25.67
Operating Margin (%)
1,679
1,423
1,445
1,414
1,484
1,630
1,774
1,922
1,856
2,334
2,050
2,122
2,147
2,294
2,551
2,314
1,954
Depreciation Expense
1,634
5,261
4,499
5,436
2,756
8,422
912
1,532
3,623
4,645
5,749
4,385
14,956
4,928
2,575
5,716
5,829
Net Income, GAAP
41.31
29.1
29.12
15.33
4.62
20.46
45.23
38.47
15.71
15.32
1.3
2.31
12.56
12.47
15.13
15.02
14.54
Effective Tax Rate (%)
5.76
19.21
17.02
20.51
11.98
35.2
3.27
5.08
11.75
13.76
23.61
17.76
51
16.25
8.21
17.5
17.78
Profit Margin (%)
3,242
1,157
-123
1,550
1,383
3,170
-2,290
-10,662
-5,564
-4,559
-1,901
-4,996
-2,041
-2,424
-4,700
-3,881
-4,668
Working Capital
14,809
12,203
14,671
15,456
15,841
15,324
14,661
14,264
20,271
23,590
23,425
20,572
17,035
15,205
14,637
14,708
14,012
LT Debt
9,745
8,827
6,737
7,812
4,936
8,878
4,963
3,489
3,672
18,357
20,808
21,342
10,096
12,795
13,086
15,956
17,422
Total Equity
7.8
20.93
16.73
18.59
15.83
8.15
12.79
16.12
22.89
13.33
9.25
10.12
15.22
20.51
15.2
21.85
20.62
Return on Invested Capital (%)
8
26.29
23.31
27.6
16.74
46.37
5.93
7.91
18.88
14.04
14.02
10.88
45.53
19.84
10.63
21.05
19.93
Return on Capital (%)
23.45
96.06
133.34
256.42
- -
- -
- -
- -
- -
- -
82.26
50.43
199.4
68.94
29.05
55.22
51.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2,856
3,012
5,044
LT Borrowings
- -
14,015
- -
LT Finance Leases
- -
693
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,026
4,013
4,020
Market Capitalization
65,273
73,822
84,237

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
17,842
17,510
17,761
Cash, Cash Equivalents & STI
3,306
3,159
3,443
Accounts Receivable, Net
7,937
5,913
7,756
Inventories
6,118
5,924
6,157
Total Current Liabilities
21,334
21,391
22,429
Payables & Accruals
- -
- -
- -
ST Debt
2,856
3,012
5,044
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.55%
0.16%
21.93%
Free Cash Flow
55.26%
-4.29%
33.15%
Net Income, GAAP
39.18%
44.9%
121.98%
Sales/Revenue/Turnover
3.97%
6.23%
4.11%
Total Cash Common Dividend
-2.67%
-6.85%
4.91%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,363
7,884
8,012
8,117
31,376
2025
7,516
7,986
8,547
8,618
32,667
2026
7,629
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.51
0.58
-0.03
0.2
1.26
2025
0.79
0.71
1
0.32
2.82
2026
0.86
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.28
0.32
0.3
0.3
1.2
2025
0.3
0.32
0.32
0.32
1.27
2026
0.32
- -
- -
- -
- -
Similar Companies
Zhejiang Int'l Group Co.,Ltd. (000411.SZ)
Psyence Group Inc. (PSYGF)
Eli Lilly and Company (LLY.DE)
Scilex Holding Company (SCLX)
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)
Santen Pharmaceutical Co., Ltd. (4536.T)
Business
GSK plc is a British multinational biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, vaccines and specialty therapies focused on respiratory/immunology, oncology, HIV and infectious diseases. Founded through the 2000 merger of Glaxo Wellcome and SmithKline Beecham with origins tracing to 1715, the company is headquartered at 79 New Oxford Street in London, England, and operates globally with manufacturing sites in 37 countries, delivering products to markets including the US, Europe, Asia and emerging regions. Its core portfolio encompasses specialty medicines such as Nucala (mepolizumab) for severe eosinophilic asthma, COPD and CRSwNP; Jemperli (dostarlimab) for endometrial cancer; Blenrep (belantamab mafodotin) for multiple myeloma; Arexvy and Shingrix vaccines for RSV and shingles respectively; a broad range of over 20 vaccines targeting meningococcal disease (e.g. Penmenvy, a 5-in-1 MenABCWY vaccine), HPV, hepatitis and influenza; HIV treatments via ViiV Healthcare including long-acting injectables like Cabenuva (cabotegravir + rilpivirine), Apretude for PrEP and investigational assets like N6LS; general medicines including inhalers for asthma/COPD, antibiotics and gepotidacin (Blujepa) for UTIs; and oncology offerings like Zejula (niraparib) for ovarian cancer. In recent developments, GSK completed the $1.15 billion acquisition of IDRx Inc. in 2025 to advance IDRX-42, a next-generation KIT inhibitor for GIST adding to its GI cancer portfolio; entered a potential $12 billion alliance with Hengrui Pharma paying $500 million upfront for rights to a COPD candidate and up to 11 respiratory, immunology and oncology programs outside greater China; acquired exclusive rights from Syndivia for a prostate cancer antibody-drug conjugate; launched or gained approvals for five new products/line extensions in 2025 including Penmenvy, Blujepa, Nucala for COPD and depemokimab (under FDA/EMA review as the first 6-month ultra-long-acting biologic for type 2 asthma and CRSwNP); announced a $30 billion US investment over five years including a $1.2 billion biologics facility in Pennsylvania; established the GSK-Oxford Cancer Immuno-Prevention Programme; and relocated its headquarters to central London while preparing for CEO transition to Luke Miels in 2026.

Company News

APIChatGPT

  • seekingalpha.com

    AI Bubble Risks Make Dividend Stocks Attractive Again

  • zacks.com

    GSK Discontinues Development of Camlipixant for Refractory Chronic Cough

  • benzinga.com

    Disappointing Data Prompts GSK to Drop Cough Drug Development

  • proactiveinvestors.co.uk

    Jefferies resumes GSK coverage at 'buy', sees 30% upside on oncology firepower

  • wsj.com

    GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment

  • reuters.com

    GSK to halt further development of cough drug after missing main goal

  • zacks.com

    GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

  • gurufocus.com

    Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

  • businesswire.com

    Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

  • proactiveinvestors.com

    UBS keeps GSK at 'neutral' with focus on chief executive's strategy update

  • proactiveinvestors.co.uk

    UBS keeps GSK at 'neutral' with focus on chief executive's strategy update

  • reuters.com

    GSK's Jemperli meets main goal in mid-stage rectal cancer trial

  • reuters.com

    GSK's targeted cancer therapy shows positive results in late-stage study

  • reuters.com

    Alector and GSK partnership to end after dementia, Alzheimer's drug failures

  • reuters.com

    Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs

  • seekingalpha.com

    Is GSK Quietly Becoming An Oncology Powerhouse

  • seekingalpha.com

    Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering

  • zacks.com

    Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout

  • zacks.com

    GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

  • globenewswire.com

    Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)